Peter Keating Dec2008
Confidentiality and trial integrity issues for monitoring adaptive design trials Paul Gallo FDA-Industry Workshop September 28, 2006.
Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated Interferon alpha-2a in treatment naïve chronic.
Breaking news from IST-3 Peter Sandercock University of Edinburgh on behalf of the IST-3 collaborative group ESC London 29 th May 2013.
HW_protocol_version_..
SIGNIFY TRIAL
1 FDA DRAFT GUIDANCE ON CLINICAL TRIAL DATA MONTORING COMMITTEES Susan S. Ellenberg, Ph.D. Office of Biostatistics and Epidemiology Center for Biologics.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
Patient Follow-up & Streamlining Data Collection
Confidentiality and trial integrity issues for monitoring adaptive design trials
John H. Alexander, MD, MHS on behalf of the APPRAISE-2 Investigators Apixaban with Antiplatelet Therapy After Acute Coronary Syndrome: Results of the APPRAISE-2.
29 th May 2013 ESC London
